Companies - May 19, 2015
AstraZeneca to Build New Swedish Facility
AstraZeneca plans to spend $285 million to build a new drug manufacturing facility in Sodertalje, Sweden, so it can produce more drugs to be used in clinical trials, according to a BioSpace.com article. The plant is expected to bring 150 to 250 “highly skilled” new jobs to the area by 2019. The new facility is being designed […]
Companies - May 19, 2015
Lundbeck, Others Call for MDD in Dictionaries
A petition supported byTakeda Pharmaceuticals U.S.A., Inc. and Lundbeck U.S. calls on popular dictionaries, including Oxford Dictionary and Dictionary.com, to consider including Major Depressive Disorder (MDD) and all of the symptoms associated with it in their dictionaries. The goal of the petition is to bring greater awareness to the disorder and its symptoms. The word […]
Acquisition - May 18, 2015
Bavarian Nordic Gets Loan
Bavarian Nordic has secured a loan facility of EUR 50 million from the European Investment Bank (EIB). The loan facility has been issued to support the research and development of vaccines against Ebola and other infectious diseases as well as cancer immunotherapies, according to BioSpace.com. The loan facility provides Bavarian Nordic a chance to speed […]
Clinical Trials - May 18, 2015
Solid Safety Profile for Heart Drug
New data from an ongoing post-marketing study evaluating the safety of once-daily XARELTO® (rivaroxaban) in patients with non-valvular atrial fibrillation (NVAF) were presented at the American Geriatrics Society 2015 Annual Scientific Meeting. “The data from this ongoing five-year observational study reaffirms the safety profile of XARELTO®, including in elderly patients who are at a particularly […]
Global report - May 15, 2015
Data Lacking on Ebola Vaccines
With Ebola nearly eliminated in West Africa, vaccine trials probably will fail to provide enough useful data on how well they protect people against the virus, the World Health Organization (WHO) said. Liberia was declared free from Ebola by the government and the WHO recently after 42 days without a new case of the virus, […]
Clinical Trials - May 15, 2015
Solid Tests for Smallpox Vaccine
Results of two pivotal Phase 3 studies of the liquid-frozen formulation of Bavarian Nordic A/S’s IMVAMUNE®, supporting a Biologics License Application for U.S. approval of the vaccine, were announced this week. In addition, the company announced results from a Phase 2 study of freeze-dried IMVAMUNE smallpox vaccine, supporting the clinical requirements for an Emergency Use […]
